|
Covidien's New R&D Centre in Hyderabad
The company intends to devote five to six per cent of sales
to R&D activities in the next few years
Harry de Wit, President, Asia, Covidien lights the ceremonial lamp |
Covidien, a global provider of healthcare products has opened
its first R&D centre in India. Known as the Covidien India Engineering Center
(CIEC), it is a 40,000 sq ft facility based in DLF Cybercity Special Economic
Zone (SEZ), Hyderabad and will be expanded into a larger facility in the future.
The CIEC offers a range of engineering services for the company’s medical
products business and in the course of time could employ up to 350 staff members.
Randel Frazier, Vice President, R&D, Emerging Markets
said, “Innovation is at the heart of everything Covidien does. The company
devotes significant resources to invent and develop technology that physicians
utilise to improve patient outcomes. Our company is expanding our R&D capabilities
worldwide and this new facility in India is playing an integral role in our
global strategy.”
Covidien has increased its R&D investments substantially
in the last five years and has launched more than 100 new products. The company
intends to devote five to six per cent of sales to R&D activities in the
next few years.
CIEC will provide engineering services to Covidien’s
R&D organisation in the areas of design, hardware, software and testing
etc.
Robert Frechette, Vice President, Engineering Services, said,
“India has a strong base of highly-talented engineers. Bringing this talent
into Covidien’s organisation is critical for our continued growth. By establishing
this presence in Hyderabad, we are expanding Covidien’s R&D capabilities
as well as enhancing the city’s reputation as a hub for life sciences.”
“Our new facility is up and running with more than 30 engineers and staff
involved in Covidien’s global R&D efforts,” added Frechette.
“With a fast-growing economy, the demand for healthcare in India is growing
at a rapid pace,” said Arjun Sarker, Managing Director, Indian subcontinent.
“The establishment of this R&D facility expands Covidien’s presence
and commitment to India,” he said.
EH News Bureau
|
